Respiratory syncytial virus (RSV) is the second most common pathogen causing infant
mortality. Additionally, RSV is a major cause of morbidity and mortality in older adults (age≥ …

Respiratory syncytial virus (RSV), an RNA virus spread by droplet infection that affects all
ages, is increasingly recognised as an important pathogen in adults, especially among older …

A systematic review and meta-analysis was designed in order to ascertain the effectiveness
of respiratory syncytial virus (RSV) vaccination in preventing lower respiratory tract diseases …

Introduction Respiratory syncytial virus (RSV) is an important cause of lower respiratory tract
disease in older adults, resulting in substantial morbidity and mortality. Methods This study …

Introduction The use of novel adjuvants in human vaccines continues to expand as their
contribution to preventing disease in challenging populations and caused by complex …

Monitoring the genetic variability of human respiratory syncytial virus (hRSV) is of paramount
importance, especially for the potential implication of key antigenic mutations on the …

Background We evaluated co-administration of adjuvanted seasonal quadrivalent influenza
vaccine (FLU-aQIV) and respiratory syncytial virus (RSV) prefusion F protein-based vaccine …

Respiratory syncytial virus (RSV) is an important cause of respiratory illness. While most
attention is paid to childhood infection, the RSV burden in adults≥ 60 y should also be …

Background The adjuvanted respiratory syncytial virus (RSV) prefusion F protein–based
vaccine (RSVPreF3 OA) is approved in adults aged≥ 60 years. We evaluated RSVPreF3 …

Introduction Understanding the differences between respiratory syncytial virus (RSV)
subgroups A and B provides insights for the development of prevention strategies and public …